Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Another AstraZeneca Shareholder Voices Criticism

By Drug Discovery Trends Editor | May 22, 2014

Another AstraZeneca shareholder has criticized the pharmaceutical company’s handling of Pfizer’s $119 billion takeover bid, saying Wednesday it was “arguably wrong” to reject it so quickly.
 
Pfizer Inc. this week raised its stock-and-cash offer for a third time this year, to 55 pounds ($93) per share. But AstraZeneca rejected the bid just hours later, saying it undervalued the company, which has promising new drugs in the pipeline.
 
Since then, some shareholders have said AstraZeneca was too quick to shoot down the bid, which Pfizer has said would not be raised again. The $119 billion deal would be the richest acquisition ever among drug makers and the third-biggest in any industry.
 
“We believe that the board was arguably wrong and acted too hastily to dismiss the latest proposal from Pfizer,” said Jim Stride, the director of UK equities for AXA Investment Managers UK, on Wednesday. AXA Investment Managers UK holds just under 1 percent of AstraZeneca’s stock.
 
Stride said AstraZeneca’s board “should not prevent an offer” from being put to the company’s shareholders.
 
Though it has said its indicative offer is final, Pfizer has until 5 p.m. local time on May 26 to make a formal bid under U.K. law. If it doesn’t, it cannot make another offer for six months. Pfizer has said it will not mount a hostile takeover bid.
 
Other institutional shareholders including Schroders, which holds a 2 percent stake, and Jupiter Fund Management, which holds 0.6 percent, have also expressed disappointment with the decision.
 
Date: May 21, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50